ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade

ARID1A (the AT-rich interaction domain 1A, also known as BAF250a) is one of the most commonly mutated genes in cancer(1,2). The majority of ARID1A mutations are inactivating mutations and lead to loss of ARID1A expression(3), which makes ARID1A a poor therapeutic target. Therefore, it is of clinical...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Nat Med
Main Authors: Shen, Jianfeng, Ju, Zhenlin, Zhao, Wei, Wang, Lulu, Peng, Yang, Ge, Zhongqi, Nagel, Zachary D., Zou, Jun, Wang, Chen, Kapoor, Prabodh, Ma, Xiangyi, Ma, Ding, Liang, Jiyong, Song, Shumei, Liu, Jinsong, Samson, Leona D., Ajani, Jaffer A., Li, Guo-Min, Liang, Han, Shen, Xuetong, Mills, Gordon B., Peng, Guang
Format: Artigo
Sprog:Inglês
Udgivet: 2018
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6076433/
https://ncbi.nlm.nih.gov/pubmed/29736026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41591-018-0012-z
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker